🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Peter A. Humphrey

Yale University

ORCID: 0009-0006-9958-9717
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5
N/A
6.9DataRank · unranked
283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier

European Urology(2020)10.1016/j.eururo.2020.09.017
N/A
0.494DataRank · unranked
26 citations

Daiki Ueno, Aydin Pooli, Neil Mendhiratta, Jamil Syed, Kevin A. Nguyen +6 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270
N/A
0.345DataRank · unranked
9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Comparative Performance of Machine Learning Models in Reducing Unnecessary Targeted Prostate Biopsies

European Urology Oncology(2025)10.1016/j.euo.2025.01.005
N/A
0.241DataRank · unranked
4 citations

Roxana Esmaili, Ghazal Khajir, Tal Zeevi, Moritz Gross, Michael Leapman +13 more

Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4562
N/A
0.104DataRank · unranked
1 citations

Catherine M. Tangen, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey, Adebowale Adeniran +9 more

Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma

British Journal of Urology(2024)10.1111/bju.16403
N/A
0.104DataRank · unranked
1 citations

Catherine M. Tangen, Melissa Plets, Xiaochen Li, Maria Tretiakova, Peter A. Humphrey +11 more

DA-SSL: self-supervised domain adaptor to leverage foundational models in turbt histopathology slides

arXiv (Cornell University)(2025)10.48550/arxiv.2512.13600
N/A
0DataRank · unranked
0 citations

Meera Chappidi, Erolcan Sayar, Helen Richards, Zhijun Chen, Lucas Liu +9 more

Data from Genomic Heterogeneity and the Small Renal Mass

(2023)10.1158/1078-0432.c.6527436.v1
N/A
0DataRank · unranked
0 citations

Zuoquan Xie, Marta Boeke, Jamil Syed, Kevin Nguyen, Patrick D. McGillivray +8 more

Analysis of 3D pathology samples using weakly supervised AI

Cell(2024)10.1016/j.cell.2024.03.035
N/A
0DataRank · unranked
98 citations

Mane Williams, Drew F. K. Williamson, Sarah S. L. Chow, Guillaume Jaume, Gan Gao +14 more

A Serological Multiplexed Immunoassay (MIA) Detects Antibody Reactivity to SARS-CoV-2 and Other Viral Pathogens in Liberia and Is Configurable as a Multiplexed Inhibition Test (MINT)

Immuno(2024)10.3390/immuno4010007
N/A
0DataRank · unranked
3 citations

Albert To, Caitlin A. Williams, Aquena H. Ball, Karalyn Fong, Teri Ann S. Wong +10 more